Nutritional vitamin D supplementation and health-related outcomes in hemodialysis patients: a protocol for a systematic review and meta-analysis

详细信息    查看全文

• 作者：Anita Mehrotra (1)
  Wai-Yin Leung (1)
  Tannia Joson (1)
  
  1. Division of Nephrology ; Department of Medicine ; Icahn School of Medicine at Mount Sinai ; One Gustave L. Levy Place ; Box 1243 ; New York ; NY ; 10029 ; USA
  
• 关键词：Vitamin D ; 25(OH)D ; Ergocalciferol (D2) ; Cholecalciferol (D3) ; Hemodialysis ; Clinical trial ; Systematic review ; Protocol
• 刊名：Systematic Reviews
• 出版年：2015
• 出版时间：December 2015
• 年：2015
• 卷：4
• 期：1
• 全文大小：331 KB
• 参考文献：1. Collins, AJ, Foley, RN, Herzog, C, Chavers, B, Gilbertson, D, Herzog, C (2013) US Renal Data System 2012 Annual Data Report. Am J Kidney Dis 61: pp. A7 CrossRef
  2. Brookhart, MA, Schneeweiss, S, Avorn, J, Bradbury, BD, Liu, J, Winkelmayer, WC (2010) Comparative mortality risk of anemia management practices in incident hemodialysis patients. JAMA 303: pp. 857-64 CrossRef
  3. Wolf, M, Shah, A, Gutierrez, O, Ankers, E, Monroy, M, Tamez, H (2007) Vitamin D levels and early mortality among incident hemodialysis patients. Kidney Int 72: pp. 1004-13 CrossRef
  4. Servilla, KS, Singh, AK, Hunt, WC, Harford, AM, Miskulin, D, Meyer, KB (2009) Anemia management and association of race with mortality and hospitalization in a large not-for-profit dialysis organization. Am J Kidney Dis 54: pp. 498-510 CrossRef
  5. Foley, RN, Parfrey, PS, Harnett, JD, Kent, GM, Murray, DC, Barre, PE (1996) The impact of anemia on cardiomyopathy, morbidity, and and mortality in end-stage renal disease. Am J Kidney Dis 28: pp. 53-61 CrossRef
  6. Ofsthun, N, Labrecque, J, Lacson, E, Keen, M, Lazarus, JM (2003) The effects of higher hemoglobin levels on mortality and hospitalization in hemodialysis patients. Kidney Int 63: pp. 1908-14 CrossRef
  7. Gracia-Iguacel, C, Gallar, P, Qureshi, AR, Ortega, O, Mon, C, Ortiz, M (2010) Vitamin D deficiency in dialysis patients: effect of dialysis modality and implications on outcome. J Ren Nutr 20: pp. 359-67 CrossRef
  8. Pecovnik-Balon, B, Jakopin, E, Bevc, S, Knehtl, M, Gorenjak, M (2009) Vitamin D as a novel nontraditional risk factor for mortality in hemodialysis patients. Ther Apher Dial 13: pp. 268-72 CrossRef
  9. Bikle, D (2009) Nonclassic actions of vitamin D. J Clin Endocrinol Metab 94: pp. 26-34 CrossRef
  10. Looker, AC, Johnson, CL, Lacher, DA, Pfeiffer, CM, Schleicher, RL, Sempos, CT (2011) Vitamin D status: United States, 2001鈥?006. NCHS Data Brief 59: pp. 1-8
  11. Holick, MF (2007) Vitamin D, deficiency. N Engl J Med 357: pp. 266-81 CrossRef
  12. Pramyothin, P, Holick, MF (2012) Vitamin D supplementation: guidelines and evidence for subclinical deficiency. Curr Opin Gastroenterol 28: pp. 139-50 CrossRef
  13. Jean, G, Terrat, JC, Vanel, T, Hurot, JM, Lorriaux, C, Mayor, B (2008) Daily oral 25-hydroxycholecalciferol supplementation for vitamin D deficiency in haemodialysis patients: effects on mineral metabolism and bone markers. Nephrol Dial Transplant 23: pp. 3670-6 CrossRef
  14. Sawinski, D, Uribarri, J, Peace, D, Yao, T, Wauhop, P, Trzcinka, P (2010) 25-OH-vitamin D deficiency and cellular alloimmunity as measured by panel of reactive T cell testing in dialysis patients. Am J Transplant 10: pp. 2287-95 CrossRef
  15. Mehrotra, R, Kermah, D, Budoff, M, Salusky, IB, Mao, SS, Gao, YL (2008) Hypovitaminosis D in chronic kidney disease. Clin J Am Soc Nephrol 3: pp. 1144-51 CrossRef
  16. Doorenbos, CR, Born, J, Navis, G, Borst, MH (2009) Possible renoprotection by vitamin D in chronic renal disease: beyond mineral metabolism. Nat Rev Nephrol 5: pp. 691-700 CrossRef
  17. Jacob, AI, Sallman, A, Santiz, Z, Hollis, BW (1984) Defective photoproduction of cholecalciferol in normal and uremic humans. J Nutr 114: pp. 1313-9
  18. Helvig, CF, Cuerrier, D, Hosfield, CM, Ireland, B, Kharebov, AZ, Kim, JW (2010) Dysregulation of renal vitamin D metabolism in the uremic rat. Kidney Int 78: pp. 463-72 CrossRef
  19. Lemire, JM, Adams, JS, Kermani-Arab, V, Bakke, AC, Sakai, R, Jordan, SC (1985) 1,25-Dihydroxyvitamin D3 suppresses human T helper/inducer lymphocyte activity in vitro. J Immunol 134: pp. 3032-5
  20. Manolagas, SC, Provvedini, DM, Tsoukas, CD (1985) Interactions of 1,25-dihydroxyvitamin D3 and the immune system. Mol Cell Endocrinol 43: pp. 113-22 CrossRef
  21. Piemonti, L, Monti, P, Sironi, M, Fraticelli, P, Leone, BE, Dal Cin, E (2000) Vitamin D3 affects differentiation, maturation, and function of human monocyte-derived dendritic cells. J Immunol 164: pp. 4443-51 CrossRef
  22. Chen, S, Sims, GP, Chen, XX, Gu, YY, Lipsky, PE (2007) Modulatory effects of 1,25-dihydroxyvitamin D3 on human B cell differentiation. J Immunol 179: pp. 1634-47 CrossRef
  23. Griffin, MD, Kumar, R (2003) Effects of 1alpha,25(OH)2D3 and its analogs on dendritic cell function. J Cell Biochem 88: pp. 323-6 CrossRef
  24. Provvedini, DM, Tsoukas, CD, Deftos, LJ, Manolagas, SC (1983) 1,25-dihydroxyvitamin D3 receptors in human leukocytes. Science 221: pp. 1181-3 CrossRef
  25. Provvedini, DM, Tsoukas, CD, Deftos, LJ, Manolagas, SC (1986) 1 alpha,25-Dihydroxyvitamin D3-binding macromolecules in human B lymphocytes: effects on immunoglobulin production. J Immunol 136: pp. 2734-40
  26. Effective Practice and Organisation of Care (EPOC), EPOC Resources for review authors. Oslo: Norwegian Knowledge Centre for the Health Services. https://epoc.cochrane.org/epoc-specific-resources-review-authors. Accessed 14 Jan 2015.
  27. Moher, D, Liberati, A, Tetzlaff, J, Altman, DG, Group, P (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 151: pp. 264-9 CrossRef
  28. Lehmann, U, Hirche, F, Stangl, GI, Hinz, K, Westphal, S, Dierkes, J (2013) Bioavailability of vitamin D(2) and D(3) in healthy volunteers, a randomized placebo-controlled trial. J Clin Endocrinol Metab 98: pp. 4339-45 CrossRef
  29. Kramer, H, Berns, JS, Choi, MJ, Martin, K, Rocco, MV (2014) 25-Hydroxyvitamin D testing and supplementation in CKD: an NKF-KDOQI controversies report. Am J Kidney Dis 64: pp. 499-509 CrossRef
  
• 刊物主题：Medicine/Public Health, general; Biomedicine general; Statistics for Life Sciences, Medicine, Health Sciences;
• 出版者：BioMed Central
• ISSN：2046-4053

文摘

Background The prevalence of vitamin D deficiency in hemodialysis patients is high. While most hemodialysis patients are treated with activated vitamin D (1,25[OH]2D) to prevent renal osteodystrophy, clinical practices of the screening and treatment of 25(OH)2D deficiency are highly variable. It is unclear if nutritional vitamin D supplementation with D2 or D3 provides an additional clinical benefit beyond that provided by activated vitamin D treatment in this population. Methods/design We will conduct a systematic review of nutritional vitamin D (D2/D3) supplementation and health-related outcomes in hemodialysis patients according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. The primary objective is to assess the impact of nutritional vitamin D supplementation on clinical outcomes relevant in hemodialysis patients, such as mortality, cardiovascular events, infections, and fractures. Secondary outcomes will include anemia, hyperparathyroidism, medication use (erythrocyte-stimulating agents, activated vitamin D), and quality of life. We will search MEDLINE, Scopus, Web of Science, and ClinicalTrials.gov for randomized, controlled trials of nutritional vitamin D supplementation (ergocalciferol/D2 or cholecalciferol/D3) in chronic hemodialysis patients. The Cochrane Risk Assessment Tool will be used to assess the quality of eligible studies. We will perform meta-analyses using standard techniques for the outcomes listed above if pooling is deemed appropriate/sufficient. The results of this systematic review may highlight gaps in our knowledge of the relevance of nutritional vitamin D in end-stage renal disease, allowing for the informed design of clinical trials assessing the impact of nutritional vitamin D therapy in the hemodialysis population in the future. Systematic review registration PROSPERO CRD42014013931